Pieris AG We are an independent, clinical stage biotechnology company advancing our proprietary Anticalin® technology to create safer, more efficacious and more convenient protein therapeutics. Exclusive to us, Anticalins are therapeutic proteins derived from human lipocalins, rationally engineered to solve for the pharmacological and pharmaceutical limitations of both protein- and non-protein-based drug platforms. We will clinically validate Anticalin therapeutics on its own and through strategic partnerships, involving both our proprietary pipeline and our de novo drug discovery capabilities. The company has closed several discovery and development collaborations across a very wide range of diseases.